A new study published in the journal Nature reports results of the first-in-human phase 1 clinical trials of a novel ...

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel ...

1 Recently, chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a promising approach in autoimmune diseases.2 We present a 39-year-old woman with erosive seropositive RA who had failed all ...

Use of the anti-CD19 CAR T-cell therapy obecabtagene autoleucel (obe-cel; Aucatzyl) resulted in durable remissions among ...

The acquisition will grant Roche full ownership over a pipeline of allogeneic CAR-T therapy candidates, including two ...

An expert highlighted unmet needs in treating T-cell acute lymphoblastic leukemia and where research may focus in the future.

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel ...

Findings suggest GD2-specific CAR T-cell therapy is a viable option for H3K27M-mutant gliomas, with significant tumor ...

Roche has struck a $1.5 billion deal to buy Poseida Therapeutics. The takeover will establish off-the-shelf cell therapies, ...

Santhosh K. Sadashiv, MD, discusses the role of chimeric antigen receptor T-cell therapy in patients with multiple myeloma.

The global CAR-T Cell Therapy market size is expected to reach USD 8.92 billion by 2026 growing at a CAGR of 34.5% from 2020 to 2026 according to a new study published by Report Ocean. Request To ...

Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with ...